Wolfgang Miesbach, Flora Peyvandi and Glenn F Pierce on Malignancy in Persons with Haemophilia
Michael Makris, Professor of Haemostasis and Thrombosis at University of Sheffield, Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared an insightful post on LinkedIn:
”There is an interesting discussion about the issue of malignancy in persons with haemophilia who have had gene therapy in the New England Journal this week.
The number of malignancies is increasing as more patients undergo gene therapy.
The key issues are:
a) Need for a standardised set of investigations
b) Need for advice on what tissue sample to collect and how to store them, to allow for the more specialised investigations
c) The interpretation of the results
d) Payment for these very expensive investigations. Manufacturers have funded these so far because most of the cases were seen in the clinical trials, but will they continue to fund it long term?”
Read the full article in NEJM.
Article: AAV Gene Therapy in Severe Hemophilia B
Authors: Wolfgang Miesbach, Flora Peyvandi, Glenn F Pierce
Saty updated on the latest scientific advances in the field of Hemophilia with Hemostasis Today.
-
Oct 13, 2025, 03:53Ganesh Mohan is Organising a Webinar to Improve Awareness About Thrombophilia on World Thrombosis Day
-
Oct 13, 2025, 02:47Thomas Reiser: Don't Miss This ISTH Research Recap with Robert Sidonio, Cedric Hermans and Michael Makris
-
Oct 12, 2025, 15:39Renjith Vijayakumar Selvarani: A Heart Attack Isn’t Just a Health Scare — It’s a Medical Emergency
-
Oct 12, 2025, 11:28Is it time for GLP1 receptor agonists in VTE care?
-
Oct 12, 2025, 11:26WFH: Women and Girls with Bleeding Disorders
-
Oct 13, 2025, 03:32Wolfgang Miesbach: This Study from Children's Hospital of Philadelphia Provides Crucial Insights Into Elevidys
-
Oct 13, 2025, 02:43Lukas Meyer and Colleagues on Reperfusion-dependent Treatment Effects of Thrombectomy in Large Ischemic Infarcts
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 12, 2025, 07:28Roberta Gualtierotti: rFVIIIFc and rFIXFc Ensured Effective Haemostasis and Favourable Safety in Major Orthopaedic Surgery
-
Oct 12, 2025, 01:32Evaluating Drug–Drug Interactions in Cancer Patients Receiving Anticoagulants and Antineoplastics
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 13, 2025, 03:44Jorge Monge: It Was An Honor to Take Part in the 3rd EBA Workshop on Rare Blood Provision
-
Oct 13, 2025, 03:15Arun V. J: They Chose Death Over A Blood Transfusion — And Here’s Why I Stopped Judging Them
-
Oct 13, 2025, 03:13Rahaf Ajaj: The Persistent Gender Gap in Nobel Prizes - A Call for Greater Inclusion
-
Oct 13, 2025, 02:50Emmanuel J Favaloro: Again Promoting World Thrombosis Day - October 13
-
Oct 12, 2025, 07:38Antonio Vega With Incredible Team Led by the Great Dr Majluf